What Is Pielotax?
Pielotax is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting kidney (renal) tissue. It belongs to the Khavinson system of organ-specific peptide bioregulators and is designed to restore normal functional gene expression in renal cells — specifically nephrons, the functional filtration units of the kidney — that decline in activity with aging. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Quick Reference
Member reference tables summarize the compound's research parameters.
Renal Aging
Kidney function declines predictably with age: GFR decreases by approximately 1 mL/min/year after age 40, glomerulosclerosis progresses, tubular secretion capacity falls, and the kidney's ability to concentrate urine diminishes. By age 80, most individuals have lost 30–40% of their renal functional reserve. Pielotax is designed to slow this decline by restoring normal nephron cell gene expression.
Research Applications
Animal studies have demonstrated improved kidney histology scores, reduced fibrosis markers, better preservation of GFR parameters, and decreased tubular injury markers in aged animals treated with Pielotax. It is used in Russian anti-aging bioregulator protocols targeting renal health and is sometimes combined with Crystagen (bladder bioregulator) and Vesilut for comprehensive urological system support.
Mechanism of Action
Tissue-selective renal metabolism normalization: Pielotax (peptide complex A-9) acts selectively on kidney tissue cells, regulating metabolic processes and normalizing renal function. Experimental and clinical data demonstrate activation of metabolism in kidney tissues and intensification of secretory function, reflected in improved biochemical markers — urea, uric acid, and creatinine — in gouty nephropathy subjects. Pielotax also exhibits anti-oxidative properties, reducing peroxide oxidation in renal tissue and lowering oxidative stress burden on nephrons. The result is increased functional reserve capacity and improved adaptation to environmental stress and metabolic load.
Short signaling peptides and gene regulation: Pielotax's low-molecular peptides (≤5000 Da) are proposed to interact directly with DNA promoter regions in renal cells — inducing local unwinding of the double helix, activating RNA polymerase, and initiating transcription of kidney-specific proteins. This nuclear-active mechanism aligns with the broader Khavinson bioregulator framework, framing Pielotax as an epigenetic modulator that restores youthful gene expression programs in aging nephron cells rather than acting through a classical receptor pathway.
Cell renewal and anti-apoptotic effects: Experimental models show that Pielotax increases synthesis of the kidney cell-division protein Ki67 by 2.2×, enhancing proliferative activity, while reducing expression of pro-apoptotic p53 by approximately 20% in kidney cells. Together these changes stimulate cell renewal in renal tissue, supporting regeneration under chronic nephrotoxic stress, ischemic injury, and age-related decline. Functional effects develop over 15–30 day courses and can persist for months after the course ends, consistent with gene-expression and protein-synthesis changes outlasting plasma peptide exposure.
Research Indications
Gouty Nephropathy
A clinical study in middle-aged patients with gouty nephropathy showed 78% of patients experienced a decrease in clinical nephropathy signs, with improvements in well-being, sleep normalization, reduced joint pain, and favorable changes in blood and urine laboratory markers. Pielotax was well tolerated — no side effects, complications, or drug dependence reported. Authors recommend it as a medical-preventive adjunct to symptomatic and pathogenetic therapy for gouty nephropathy.
Nephropathy Adjunctive Therapy (Clinical)
Russian clinical practice data support Pielotax as a component of complex therapy for various kidney diseases, normalizing metabolism and function of kidney cells. Clinical protocols combine it with standard nephropathy medications (allopurinol, RAAS blockers) without reported major interactions.
Gouty NephropathySupported Research
Nephroprotection in Experimental Injury Models
Experimental data show nephroprotective effects in models of ischemic kidney injury, gentamicin nephropathy, and cisplatin-induced acute renal failure, supporting recovery of both kidney structure and function. Cell renewal markers (Ki67 ↑ 2.2×; p53 ↓ 20%) confirm regenerative activity in renal tissue models.
Renal Aging and GFR Preservation
Long-term animal bioregulator studies report 20–40% increases in mean lifespan when short signaling peptides are used from mid-life onward. Human preventive use data from Russian literature associates periodic peptide courses with rehabilitation of physiological functions over 6–12 year follow-up periods, though study methodology and controls are limited.
Nephroprotection in Experimental Injury ModelsPreliminary Data
CKD Support and Functional Reserve Restoration
Contemporary integrative clinicians discuss Pielotax as a potential adjunct in CKD management, aiming to restore natural kidney function and enhance effects of other medications. This application is experimental — no controlled trials in CKD populations exist outside Russian observational literature.
CKD Support and Functional Reserve RestorationPreclinical Only
Research Protocols (Educational Only)
This member section describes parameters reported in the research literature.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Reported Research Time Points
This member section summarizes reported research time points.
Research Citations
- Peptide bioregulators as a new class of geroprotectors: from laboratory research to clinical studies
Khavinson V, Linkova N, Diatlova A, Trofimova S — Biomedicines, 2021 - Peptide regulation of aging — Khavinson bioregulator family review
Khavinson VKh, Linkova NS et al. — Bull Exp Biol Med, 2013 - Short peptides regulate gene expression, protein synthesis and replicative lifespan of human fibroblasts
Khavinson VKh et al. — Bull Exp Biol Med, 2014 - Correction of impaired glucose tolerance using tetrapeptide in old female rhesus monkeys — Khavinson bioregulator NHP model
Goncharova ND, Ivanova LG, Oganyan TE — Adv Gerontol, 2015 - Geroprotective effects of peptide bioregulators in aging: current status and prospects
Khavinson VKh, Linkova NS et al. — Adv Gerontol, 2023 - Khavinson development attribution. Existing stored entry reference; Existing stored entry reference
Pielotax is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting kidney (renal) tissue. It belongs to the Khavinson system of organ-specific peptide bioregulators and is designed to restore normal functional gene expression in renal cells — specifically nephrons, the functional filtration units of the kidney — that decline in activity with aging.